BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 27462861)

  • 1. Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors.
    Wood O; Woo J; Seumois G; Savelyeva N; McCann KJ; Singh D; Jones T; Peel L; Breen MS; Ward M; Garrido Martin E; Sanchez-Elsner T; Thomas G; Vijayanand P; Woelk CH; King E; Ottensmeier C;
    Oncotarget; 2016 Aug; 7(35):56781-56797. PubMed ID: 27462861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
    Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
    Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peritumoral cuffing by T-cell tumor-infiltrating lymphocytes distinguishes HPV-related oropharyngeal squamous cell carcinoma from oral cavity squamous cell carcinoma.
    Poropatich K; Hernandez D; Fontanarosa J; Brown K; Woloschak G; Paintal A; Raparia K; Samant S
    J Oral Pathol Med; 2017 Nov; 46(10):972-978. PubMed ID: 28632936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of B lymphocyte infiltration in HPV
    Zhang S; Wang B; Ma F; Tong F; Yan B; Liu T; Xie H; Song L; Yu S; Wei L
    Cancer Sci; 2021 Apr; 112(4):1402-1416. PubMed ID: 33529452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-Cell Transcriptome Analysis Reveals Different Immune Signatures in HPV- and HPV + Driven Human Head and Neck Squamous Cell Carcinoma.
    Li S; Wang Y; Sun R; Franceschi D; Pan H; Wei C; Ogbuehi AC; Lethaus B; Savkovic V; Gaus S; Zimmerer R; Ziebolz D; Schmalz G; Jiang X
    J Immunol Res; 2022; 2022():2079389. PubMed ID: 36157879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Digital pathology-aided assessment of tumor-infiltrating T lymphocytes in advanced stage, HPV-negative head and neck tumors.
    de Ruiter EJ; de Roest RH; Brakenhoff RH; Leemans CR; de Bree R; Terhaard CHJ; Willems SM
    Cancer Immunol Immunother; 2020 Apr; 69(4):581-591. PubMed ID: 31980916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological network analysis in HPV associated head and neck squamous cancer and implications for disease prognosis.
    Chen X; Yan B; Lou H; Shen Z; Tong F; Zhai A; Wei L; Zhang F
    Mol Immunol; 2018 Apr; 96():28-36. PubMed ID: 29477933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulated glycolysis correlates with tumor progression and immune evasion in head and neck squamous cell carcinoma.
    Takahashi H; Kawabata-Iwakawa R; Ida S; Mito I; Tada H; Chikamatsu K
    Sci Rep; 2021 Sep; 11(1):17789. PubMed ID: 34493792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oropharyngeal squamous cell carcinomas differentially express granzyme inhibitors.
    van Kempen PM; Noorlag R; Swartz JE; Bovenschen N; Braunius WW; Vermeulen JF; Van Cann EM; Grolman W; Willems SM
    Cancer Immunol Immunother; 2016 May; 65(5):575-85. PubMed ID: 26993499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas.
    Kong CS; Narasimhan B; Cao H; Kwok S; Erickson JP; Koong A; Pourmand N; Le QT
    Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):553-61. PubMed ID: 19427557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of HPV status on immune responses in head and neck squamous cell carcinoma.
    Qureshi HA; Zhu X; Yang GH; Steadele M; Pierce RH; Futran ND; Lee SM; Méndez E; Houghton AM
    Oral Oncol; 2022 Apr; 127():105774. PubMed ID: 35219073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
    Seiwert TY; Zuo Z; Keck MK; Khattri A; Pedamallu CS; Stricker T; Brown C; Pugh TJ; Stojanov P; Cho J; Lawrence MS; Getz G; Brägelmann J; DeBoer R; Weichselbaum RR; Langerman A; Portugal L; Blair E; Stenson K; Lingen MW; Cohen EE; Vokes EE; White KP; Hammerman PS
    Clin Cancer Res; 2015 Feb; 21(3):632-41. PubMed ID: 25056374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.
    Badoual C; Hans S; Merillon N; Van Ryswick C; Ravel P; Benhamouda N; Levionnois E; Nizard M; Si-Mohamed A; Besnier N; Gey A; Rotem-Yehudar R; Pere H; Tran T; Guerin CL; Chauvat A; Dransart E; Alanio C; Albert S; Barry B; Sandoval F; Quintin-Colonna F; Bruneval P; Fridman WH; Lemoine FM; Oudard S; Johannes L; Olive D; Brasnu D; Tartour E
    Cancer Res; 2013 Jan; 73(1):128-38. PubMed ID: 23135914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral blood monocyte and T-lymphocyte activation levels at diagnosis predict long-term survival in head and neck squamous cell carcinoma patients.
    Aarstad HJ; Vintermyr OK; Ulvestad E; Aarstad HH; Kross KW; Heimdal JH
    APMIS; 2015 Apr; 123(4):305-14. PubMed ID: 25801083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival-related indicators ALOX12B and SPRR1A are associated with DNA damage repair and tumor microenvironment status in HPV 16-negative head and neck squamous cell carcinoma patients.
    Li J; Tang LL; Ma J
    BMC Cancer; 2022 Jun; 22(1):714. PubMed ID: 35768785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interplay between HPV and host immunity in head and neck squamous cell carcinoma.
    Andersen AS; Koldjaer Sølling AS; Ovesen T; Rusan M
    Int J Cancer; 2014 Jun; 134(12):2755-63. PubMed ID: 23913554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.
    Hajek M; Sewell A; Kaech S; Burtness B; Yarbrough WG; Issaeva N
    Cancer; 2017 May; 123(10):1778-1790. PubMed ID: 28295222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human papillomavirus-associated head and neck squamous cell carcinoma survival: a comparison by tumor site and initial treatment.
    Salazar CR; Smith RV; Garg MK; Haigentz M; Schiff BA; Kawachi N; Anayannis N; Belbin TJ; Prystowsky MB; Burk RD; Schlecht NF
    Head Neck Pathol; 2014 Mar; 8(1):77-87. PubMed ID: 24002971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
    Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
    Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.
    Pogorzelski M; Ting S; Gauler TC; Breitenbuecher F; Vossebein I; Hoffarth S; Markowetz J; Lang S; Bergmann C; Brandau S; Jawad JA; Schmid KW; Schuler M; Kasper S
    Cell Death Dis; 2014 Feb; 5(2):e1091. PubMed ID: 24577089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.